These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 9649160

  • 1. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
    Baldini E, Tibaldi C, Ardizzoni A, Salvati F, Antilli A, Portalone L, Barbera S, Romano F, De Marinis F, Migliorino MR, Noseda MA, Borghini U, Crippa M, Ferrara G, Raimondi M, Fioretti M, Bandera M, Pennucci MC, Galeasso G, Cacciani GC, Lepidini G, Sunseri G, Lanfranco C, Rinaldi M, Rosso R.
    Br J Cancer; 1998 Jun; 77(12):2367-70. PubMed ID: 9649160
    [Abstract] [Full Text] [Related]

  • 2. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
    Gebbia V, Galetta D, Riccardi F, Gridelli C, Durini E, Borsellino N, Gebbia N, Valdesi M, Caruso M, Valenza R, Pezzella G, Colucci G, Gruppo Oncologico Italia Meridionale.
    Lung Cancer; 2002 Aug; 37(2):179-87. PubMed ID: 12140141
    [Abstract] [Full Text] [Related]

  • 3. Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force.
    Ardizzoni A, Addamo GF, Baldini E, Borghini U, Portalone L, De Marinis F, Lionetto R, Conte PF, Bruzzi P, Pennucci MC.
    Br J Cancer; 1995 Jan; 71(1):115-9. PubMed ID: 7529522
    [Abstract] [Full Text] [Related]

  • 4. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).
    Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, O'Brien M, Dunlop D, O'Byrne K, Laurence V, Snee M, Dark G, Thatcher N.
    Ann Oncol; 2006 Jul; 17(7):1111-9. PubMed ID: 16603599
    [Abstract] [Full Text] [Related]

  • 5. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
    Gridelli C, Perrone F, Palmeri S, D'Aprile M, Cognetti F, Rossi A, Gebbia V, Pepe R, Veltri E, Airoma G, Russo A, Incoronato P, Scinto AF, Palazzolo G, Natali M, Leonardi V, Gallo C, De Placido S, Bianco AR.
    Ann Oncol; 1996 Oct; 7(8):821-6. PubMed ID: 8922196
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
    Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N.
    Cancer; 2003 Aug 01; 98(3):542-53. PubMed ID: 12879472
    [Abstract] [Full Text] [Related]

  • 9. Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group.
    González Barón M, Feliu J, Espinosa E, García Girón C, Blanco E, Garrido P, Colmenarejo A, Ordóñez A, Moyano A, de la Gándara I.
    Ann Oncol; 1994 Apr 01; 5(4):323-7. PubMed ID: 8075028
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Français de Pneumo-Cancérologie'.
    Pérol M, Guérin JC, Thomas P, Poirier R, Carles P, Robinet G, Kleisbauer JP, Paillotin D, Vergnenègre A, Balmes P, Touron D, Grivaux M, Pham E.
    Lung Cancer; 1996 Feb 01; 14(1):119-34. PubMed ID: 8696715
    [Abstract] [Full Text] [Related]

  • 12. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A, Favaretto A, Oniga F, Festi G, Lauro S, Morabito A, Ossana L, Sartore F, DePoli F, Fiorentino MV.
    Cancer; 1996 Oct 15; 78(8):1701-7. PubMed ID: 8859183
    [Abstract] [Full Text] [Related]

  • 13. Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
    Song SY, Kim WS, Kim K, Jung CW, Im YH, Kim HJ, Kang WK, Lee HG, Kwon OJ, Rhee CH, Park CH, Park K.
    Jpn J Clin Oncol; 2003 Oct 15; 33(10):509-13. PubMed ID: 14623918
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A phase II study of vinorelbine, mitomycin C and cisplatin chemotherapy for advanced non-small cell lung cancer.
    Kwon MR, Jeong TY, Yuh YJ, Kim SR.
    Korean J Intern Med; 2002 Dec 15; 17(4):240-4. PubMed ID: 12647638
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of vinorelbine, ifosfamide, and cisplatin combination chemotherapy in advanced non-small-cell lung cancer.
    Ahn JB, Ko WK, Lee JG, Shim KY, Jeung HC, Park JO, Yoo NC, Kim BS, Kim SK, Kim SK, Kim JH.
    Am J Clin Oncol; 2000 Dec 15; 23(6):622-8. PubMed ID: 11202811
    [Abstract] [Full Text] [Related]

  • 20. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    Sculier JP, Lafitte JJ, Paesmans M, Thiriaux J, Alexopoulos CG, Baumöhl J, Schmerber J, Koumakis G, Florin MC, Zacharias C, Berghmans T, Mommen P, Ninane V, Klastersky J.
    Br J Cancer; 2000 Nov 15; 83(9):1128-35. PubMed ID: 11027424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.